The Latest Cardiac and Vascular News
MINNEAPOLIS, Aug. 29, 2025 /PRNewswire/ — Phraxis, Inc., a leader in vascular access innovation, today announced the successful completion of the first commercial case using the EndoForce™ Anastomotic Connector, marking a historic milestone in the treatment of dialysis patients worldwide….
New FDA-approved Minima Stent grows with a child’s heart, preventing the need for open heart surgeries MIAMI, Aug. 28, 2025 /PRNewswire/ — Nicklaus Children’s Hospital’s Heart Institute is ushering in a new era of cardiac treatment for children across South Florida. Nicklaus Children’s…
KIRKLAND, Wash., Aug. 28, 2025 (GLOBE NEWSWIRE) — Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced that it will report first quarter fiscal 2026 financial results on Thursday, September 11. Management will host a corresponding conference call at 4:30 p.m. Eastern Time. A live and archived webcast of the conference call will be available in the “Events” section of the investor relations website. Participants are encouraged to register on the website at least 10 minutes prior to the start of the conference call. About KestraKestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, visit www.kestramedical.com. CONTACT: Investor contact
Neil Bhalodkar
neil.bhalodkar@kestramedical.com
BROOKLYN PARK, Minn., Aug. 28, 2025 (GLOBE NEWSWIRE) — Cirtec Medical, a leading strategic outsourcing partner for complex minimally invasive, active implantable devices and precision components, is pleased to announce the appointment of Shar Matin as Chief Executive Officer, effective September 2, 2025. Shar brings more than 25 years of global leadership experience in the medical technology sector, with a proven track record of scaling businesses, driving innovation, and building strong customer partnerships. He most recently served as CEO of Cordis, where he led the successful transformation from a division of Cardinal Health to one of the world’s largest pure-play cardiovascular companies, including spearheading the acquisition of MedAlliance’s drug-eluting balloon technology. Prior to Cordis, Shar held senior executive roles at ViewRay Technologies, Spectranetics (acquired by Royal Philips), Boston Scientific, and Guidant (acquired by Boston Scientific and Abbott Laboratories). Through these roles, he consistently delivered growth through new product innovation, strategic acquisitions, and global expansion. Shar started his career as a process and manufacturing engineer. He holds an MBA from Harvard Business School and a Bachelor of Science in Mechanical Engineering from the University of California, Berkeley. Shar also serves on the Board of Directors for Koru Medical Systems (NASDAQ: KRMD). “Shar is an experienced leader with a demonstrated ability to accelerate growth, strengthen customer partnerships, and drive innovation,” said Rich Relyea, Cirtec Board member and 3i Private Equity Partner. “On behalf of the Board, we are excited to welcome him to Cirtec and are confident he will build on the company’s strong foundation and help shape its next chapter of success.” Reflecting on his appointment, Shar shared: “Cirtec has tremendous momentum, and I am humbled and privileged to lead the company into its next phase of growth while building on the incredible foundation already in place. Together with our teammates and as a trusted partner to our customers, I look forward to fulfilling our mission of bringing life-changing medical technologies to market for the betterment of patient care.” The Cirtec Board of Directors also expressed its gratitude to Brian Highley for his leadership of Cirtec over the past decade. “Brian transformed Cirtec over the course of 11 years into an industry-leading CDMO with remarkable growth and expansion. His vision and commitment have been instrumental in establishing Cirtec as a trusted partner to some of the world’s most innovative medical technology companies, and we thank Brian for all his contributions to building Cirtec into the leader that it is today.” The Board also thanks Ed Philbin, who served as Interim CEO over the past several months, for his leadership during the transition period. His dedication and support have been key in continuing Cirtec’s momentum and delivering a seamless handover to new leadership. About Cirtec Medical Cirtec Medical is a global leader in design, development, and manufacturing of complex Class II and III medical devices, specializing in active implant systems, interventional devices, and precision components. Since 1987, Cirtec Medical has built extensive in-house capabilities that enable the company to serve as a single-source partner and collaborate with customers to transform their technology into innovative medical devices across a wide array of therapies, including cardiology, neurology, orthopedics and other minimally invasive device applications. Cirtec Medical’s deep expertise in precision component design and manufacturing supports every stage of the product lifecycle, ensuring uncompromising quality and performance. With 11 global facilities and a vertically integrated approach, Cirtec Medical aims to expedite time to market, reduce risk, and accelerate revenue generation for our partners. Learn more at CirtecMed.com. For Media Inquiries Abby Kupka Sr. Manager, Marketing Cirtec Medical (763) 235-8835
BORDEAUX, France–(BUSINESS WIRE)–HeartFocus, the revolutionary, AI-enabled cardiac imaging software developed by data-driven medtech company DESKi, today announced its U.S. commercial launch. HeartFocus will initially be available on Butterfly Network’s handheld ultrasound devices, the FDA-cleared software enables any healthcare professional to conduct diagnostic-quality heart ultrasounds after just hours of training. Health […]
SAN DIEGO–(BUSINESS WIRE)–Vektor Medical, a medical technology company transforming cardiac arrhythmia care, today announced the appointment of Kelly Perez as Chief Financial Officer (CFO) and Senior Vice President of Operations, strengthening its leadership team as adoption of vMap accelerates. Perez will help guide Vektor’s financial strategy and operations to support […]
Data from acute and chronic pressure-volume loop studies support the mechanism of action and show a favorable impact of AVIM therapy on blood pressure and cardiovascular hemodynamicsAVIM therapy drove statistically significant reductions in systolic blood pressure, intra-cardiac volumes, total peripheral resistance and stroke work, with no adverse impact on stroke volume or contractility.Orchestra BioMed and Medtronic (NYSE: MDT) have a strategic collaboration for the development of AVIM therapy for treatment of uncontrolled hypertension in patients indicated for a pacemaker; over 750,000 patients annually that receive pacemakers worldwide are also believed to have hypertension. AVIM therapy has FDA Breakthrough Device Designation for the treatment of uncontrolled hypertension in patients with increased cardiovascular risk, a population the Company estimates to comprise over 7.7 million patients in the U.S. NEW HOPE, Pa., Aug. 26, 2025 (GLOBE NEWSWIRE) — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the publication of data in the Journal of the American College of Cardiology: Clinical Electrophysiology (“JACC: Clinical EP”) from a pressure-volume (“PV”) loop study demonstrating favorable hemodynamic effects of AVIM therapy in pacemaker-indicated patients with uncontrolled hypertension. AVIM therapy is currently being evaluated in the BACKBEAT global pivotal study, which Orchestra BioMed is conducting in collaboration with Medtronic, to support potential future global regulatory approvals and commercialization of AVIM therapy-enabled devices. The publication, titled “Pressure-Volume Analysis Demonstrates Short- and Long-Term Hemodynamic Effects of Atrioventricular Interval Modulation Therapy in Hypertension,” reports findings from an invasive PV loop analysis in 16 hypertensive pacemaker-indicated subjects, as well as noninvasive PV loop analysis from a subgroup of subjects (n=32) from the MODERATO II study receiving chronically administered AVIM therapy. The analyses demonstrated that AVIM therapy reduced systolic blood pressure (“SBP”) acutely by decreasing cardiac preload and effective arterial elastance unrelated to pacing lead location, while also improving left ventricular (“LV”) end-diastolic and end-systolic volumes. Chronically administered AVIM therapy demonstrated sustained reductions in SBP and end-diastolic volume, indicative of favorable reverse LV remodeling. Results also demonstrated consistently favorable hemodynamic effects using traditional right ventricular (“RV”) and conduction system pacing (“CSP”) lead placements. Daniel Burkhoff, M.D., Ph.D., Director, Heart Failure, Hemodynamics, and MCS Research, Cardiovascular Research Foundation and a manuscript author commented: “Pressure-volume loop analysis is regarded as the gold standard for assessing systolic and diastolic function as well as reverse remodeling. These results provide powerful insights on the impact of AVIM therapy to both decrease blood pressure and favorably impact ventricular end-diastolic volume without compromising cardiac output or increasing workload. Notably, these favorable effects were observed consistently and with different pacing lead locations, demonstrating the versatility of AVIM therapy. Publication of these data in a prestigious peer-reviewed journal such as JACC: Clinical Electrophysiology provides further validation from the clinical community reinforcing the therapeutic rationale behind AVIM therapy and further highlighting its potential to deliver differentiated clinical benefit for patients with uncontrolled hypertension.” Key findings include: Significantly reduced (p
August 27, 2025
RALEIGH, N.C., Aug. 26, 2025 /PRNewswire/ — Core Sound Imaging, the company behind the widely established Studycast® medical imaging workflow platform, today announced the acquisition of UltraLinQ Healthcare Solutions, a trusted provider of cloud-based PACS and cardiac monitoring…
TOKYO–(BUSINESS WIRE)–Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) announced that the Paradise™ Ultrasound Renal Denervation (uRDN) system has received approval for manufacturing and marketing in Japan for the treatment of resistant hypertension on August 25. This marks the first approval in the country for a medical device indicated for […]
